ROSEN, A RANKED AND LEADING FIRM, Encourages Medtronic plc Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action – MDT

WHAT TO DO NEXT: To join the Medtronic class action, go to https://rosenlegal.com/submit-form/?case_id=8603 or call Phillip Kim, Esq.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Friday, October 28, 2022
Information
Tags: 
Class Action Lawsuit, Professional Services, Legal, Titan, LinkedIn, Advertising, Regulation of tobacco by the U.S. Food and Drug Administration, Class, Risk assessment, Facebook, Risk, Food, THE, WHY, MDT, I-Space (Chinese company), Court, TO, Twitter, Lists of schools in England, NYSE, Security (finance), Insurance, Tobacco, Medtronic
Geotags: 
UNITED STATES, NORTH AMERICA, NEW YORK
Organisation: 
THE ROSEN LAW FIRM, P.A.
Stock Symbol: 
NYSE:MDT
Summary
Key Points: 
  • WHAT TO DO NEXT: To join the Medtronic class action, go to https://rosenlegal.com/submit-form/?case_id=8603 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.


WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Medtronic plc (NYSE: MDT) between June 8, 2019 and May 25, 2022, both dates inclusive (the “Class Period”), of the important November 7, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Medtronic securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Medtronic class action, go to https://rosenlegal.com/submit-form/?case_id=8603 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 7, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Medtronic’s product quality control systems were inadequate; (2) Medtronic had failed to comply with numerous regulations regarding risk assessment, corrective and preventive action, complaint handling, device recalls, and reporting of adverse events; (3) these failures increased the risk of regulatory investigation and action; (4) as a result of Medtronic’s misconduct, the U.S. Food and Drug Administration (“FDA”) would delay the approval of additional Medtronic MiniMed devices, including the MiniMed 780G; (5) these delays in product approvals, as well as the Company’s need to improve its quality control systems, would negatively affect Medtronic’s financial performance and cause it to fall further behind its competitors; and (6) as a result of the foregoing, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Medtronic class action, go to https://rosenlegal.com/submit-form/?case_id=8603 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Copyright: 
Copyright Business Wire 2022